Skip to menu Skip to content Skip to footer

2025

Journal Article

Point-of-care intestinal ultrasound impacts inflammatory bowel disease care and reduces the need for additional investigations

Tan, Wei-Lian, Khoo, Emi, Khaing, Myat-Myat, Barr, Emily, Fernandes, Richard G., Pham, Hai, An, Yoon-Kyo and Begun, Jakob (2025). Point-of-care intestinal ultrasound impacts inflammatory bowel disease care and reduces the need for additional investigations. Journal of Gastroenterology and Hepatology, 40 (10), 2472-2481. doi: 10.1111/jgh.70019

Point-of-care intestinal ultrasound impacts inflammatory bowel disease care and reduces the need for additional investigations

2025

Journal Article

Pathogenic OTUD3 mutations predispose to ulcerative colitis due to barrier dysfunction

Giri, Rabina, Lee, Minyi, Magor, Graham, Bergot, Anne-Sophie, He, Yaowu, Kryza, Thomas, Khan, Tashbib, Schreiber, Veronika, Gordon, Robert J., Zagani, Rachid, Hasnain, Sumaira Z., Lourie, Rohan, Ewing, Adam, Hooper, John D., Thomas, Ranjeny, Florin, Timothy H., Perkins, Andrew, Gala, Manish and Begun, Jakob (2025). Pathogenic OTUD3 mutations predispose to ulcerative colitis due to barrier dysfunction. Cellular and Molecular Gastroenterology and Hepatology 101659, 101659. doi: 10.1016/j.jcmgh.2025.101659

Pathogenic OTUD3 mutations predispose to ulcerative colitis due to barrier dysfunction

2025

Journal Article

Pro-inflammatory macrophages transporting gut-derived bacterial DNA drive autoimmune arthritis in spondyloarthropathy

Cai, Benjamin, Giri, Rabina, Cameron, Amy J., Rahman, M. Arifur, Small, Annabelle, Altmann, Christopher, Lim, Yenkai, Rehaume, Linda M., Morrison, Mark, Wechalekar, Mihir D., Begun, Jakob, Bergot, Anne-Sophie and Thomas, Ranjeny (2025). Pro-inflammatory macrophages transporting gut-derived bacterial DNA drive autoimmune arthritis in spondyloarthropathy. JCI Insight, 10 (17) e188028. doi: 10.1172/jci.insight.188028

Pro-inflammatory macrophages transporting gut-derived bacterial DNA drive autoimmune arthritis in spondyloarthropathy

2025

Journal Article

IBD 2024: charting a new course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, Australia

Mahadevan, Uma, Jairath, Vipul, Begun, Jakob, Pudipeddi, Aviv, Garg, Mayur, De Cruz, Peter, Li Wai Suen, Christopher F. D., Choy, Matthew C., Con, Danny, Vaughan, Rose, Chetwood, John D., Clark, David A., Haifer, Craig, Sparrow, Miles P., Leong, Rupert and Mountifield, Réme (2025). IBD 2024: charting a new course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, Australia. Journal of Gastroenterology and Hepatology, 40 (S3), 3-22. doi: 10.1111/jgh.70020

IBD 2024: charting a new course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, Australia

2025

Journal Article

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

Gilmore, Robert, Fernandes, Richard, Hartley, Imogen, Arzivian, Arteen, Leong, Rupert, Andrew, Bridgette, Vasudevan, Abhinav, Greeve, Tessa, Moore, Gregory Thomas, Kim, Steven, Lightowler, Daniel, Singh, Abhey, Mahy, Gillian, Mithanthaya, Aditya, Venugopaul, Kannan, Han, Sangwoo, Bryant, Robert, West, Jack, Segal, Jonathan, Christensen, Britt, Corte, Crispin, Ding, Nik, An, Yoon-Kyo and Begun, Jakob (2025). Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research, 23 (3), 347-357. doi: 10.5217/ir.2024.00127

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

2025

Journal Article

Early infliximab levels and clearance predict outcomes after infliximab rescue in acute severe ulcerative colitis: Results from PREDICT-UC

Li Wai Suen, Christopher F.D., Choy, Matthew C., Con, Danny, Cheng, Kaylene, Nigro, Julie, Breheney, Kerry, Boyd, Kristy, Pena, Raquel, Burrell, Kathryn, Rosella, Ourania, Proud, David, Brouwer, Richard, Gorelik, Alexandra, Liew, Danny, Connell, William, Wright, Emily K., Taylor, Kirstin, Pudipeddi, Aviv, Sawers, Michelle, Christensen, Britt, Ng, Watson., Begun, Jakob, Radford-Smith, Graham L., Garg, Mayur, Martin, Neal, van Langenberg, Daniel R., Ding, Nik S., Beswick, Lauren, Leong, Rupert W. ... De Cruz, Peter (2025). Early infliximab levels and clearance predict outcomes after infliximab rescue in acute severe ulcerative colitis: Results from PREDICT-UC. Gastroenterology. doi: 10.1053/j.gastro.2025.07.020

Early infliximab levels and clearance predict outcomes after infliximab rescue in acute severe ulcerative colitis: Results from PREDICT-UC

2025

Journal Article

Expert position statement: defining the role of intestinal ultrasound in assessing constipation and faecal loading

Mathias, Ryan M., Goodsall, Thomas M., Parker, Claire E., Day, Alice S., An, Yoon K., Baraty, Brandon, Basnayake, Chamara, Begun, Jakob, Boyapati, Ray K., Burgell, Rebecca, Dolinger, Michael T., Maconi, Giovanni, Novak, Kerri L., Sagami, Shintaro, Smith, Rebecca L., Srinivasan, Ashish R., Taylor, Stuart A., Jairath, Vipul, Ma, Christopher and Bryant, Robert V. (2025). Expert position statement: defining the role of intestinal ultrasound in assessing constipation and faecal loading. Alimentary Pharmacology and Therapeutics, 62 (8), 799-808. doi: 10.1111/apt.70250

Expert position statement: defining the role of intestinal ultrasound in assessing constipation and faecal loading

2025

Journal Article

Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease

Gilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Swe, Ei, An, Yoon-Kyo and Begun, Jakob (2025). Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease. Intestinal Research, 23 (4), 475-482. doi: 10.5217/ir.2024.00174

Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease

2025

Journal Article

Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis

Cui, Cedric S., Lerskiatiphanich, Titaya, Li, Xaria X., Giri, Rabina, Liu, Ning, Kumar, Vinod, Whittaker, Andrew K., Han, Felicity Y., Clark, Richard J., Begun, Jakob, Lee, John D. and Woodruff, Trent M. (2025). Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis. British Journal of Pharmacology, 182 (16), 3852-3869. doi: 10.1111/bph.70056

Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis

2025

Journal Article

The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring

Gilmore, Robert, Fernandes, Richard, Schildkraut, Tamar, Joshi, Riddhi, Lin, Lyman, Vorgin, Sara, Etchegaray, Amirah, Shanmuga Anandan, Aathavan, Tambakis, George, Loebenstein, Moshe, An, Yoon-Kyo, Begun, Jakob and Wright, Emily K (2025). The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring. Crohn's and Colitis 360, 7 (2) otaf028, 1-9. doi: 10.1093/crocol/otaf028

The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring

2025

Journal Article

SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome

Tillett, Bree J., Dwiyanto, Jacky, Secombe, Kate R., George, Thomas, Zhang, Vivian, Anderson, Dovile, Duggan, Emily, Giri, Rabina, Loo, Dorothy, Stoll, Thomas, Morrison, Mark, Begun, Jakob, Hill, Michelle M., Gurzov, Esteban N., Bell, Kirstine J., Saad, Sonia, Barlow, Christopher K., Creek, Darren J., Chong, Chun Wie, Mariño, Eliana and Hamilton-Williams, Emma E. (2025). SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome. Nature Communications, 16 (1) 2893, 1-20. doi: 10.1038/s41467-025-58319-y

SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome

2025

Journal Article

Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations

Moniruzzaman, Md, Wong, Kuan Yau, Janjua, Taskeen Iqbal, Martin, Jennifer H., Begun, Jakob and Popat, Amirali (2025). Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations. ACS Pharmacology and Translational Science, 8 (2), 543-556. doi: 10.1021/acsptsci.4c00644

Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations

2025

Journal Article

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition

Akyüz, Filiz, An, Yoon Kyo, Begun, Jakob, Aniwan, Satimai, Bui, Huu Hoang, Chan, Webber, Choi, Chang Hwan, Chopdat, Nazeer, Connor, Susan J, Desai, Devendra, Flanagan, Emma, Kobayashi, Taku, Lai, Allen Yu-Hung, Leong, Rupert W, Leow, Alex Hwong-Ruey, Leung, Wai Keung, Limsrivilai, Julajak, Muzellina, Virly Nanda, Peddi, Kiran, Ran, Zhihua, Wei, Shu Chen, Sollano, Jose, Teo, Michelle Mui Hian, Wu, Kaichun, Ye, Byong Duk and Ooi, Choon Jin (2025). Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition. Intestinal Research, 23 (1), 37-55. doi: 10.5217/ir.2024.00089

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition

2025

Journal Article

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply

Mathias, Ryan M., Goodsall, Thomas M., Parker, Claire E., Day, Alice S., An, Yoon K., Baraty, Brandon, Basnayake, Chamara, Begun, Jakob, Boyapati, Ray K., Burgell, Rebecca, Dolinger, Michael T., Maconi, Giovanni, Novak, Kerri L., Sagami, Shintaro, Smith, Rebecca L., Srinivasan, Ashish R., Taylor, Stuart A., Jairath, Vipul, Ma, Christopher and Bryant, Robert V. (2025). Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply. Alimentary Pharmacology and Therapeutics, 62 (8), 855-856. doi: 10.1111/apt.70338

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply

2025

Journal Article

Epidemiology and treatment patterns of fistulizing Crohn's disease in a large, real-world Australasian cohort

McNamara, Jack, Wilson, William, Pipicella, Joseph L., Ghaly, Simon, Begun, Jakob, Lawrance, Ian C., Gearry, Richard, Andrews, Jane M. and Connor, Susan J. (2025). Epidemiology and treatment patterns of fistulizing Crohn's disease in a large, real-world Australasian cohort. Gastro Hep Advances, 4 (4) 100594, 100594. doi: 10.1016/j.gastha.2024.100594

Epidemiology and treatment patterns of fistulizing Crohn's disease in a large, real-world Australasian cohort

2025

Journal Article

Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case report

Huynh, David, Khaing, Myat Myat, Fernandes, Richard Gareth, Malloy, Reuben, Lin, Lei, Gilmore, Robert, Walker, Nicole, Khoo, Emi and Begun, Jakob (2025). Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case report. Case Reports in Gastroenterology, 19 (1), 1-6. doi: 10.1159/000542711

Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case report

2024

Journal Article

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

Rubin, David T., Allegretti, Jessica R, Panés, Julián, Shipitofsky, Nicole, Yarandi, Shadi S, Huang, Kuan-Hsiang Gary, Germinaro, Matthew, Wilson, Rebbecca, Zhang, Hongyan, Johanns, Jewel, Feagan, Brian G, Hisamatsu, Tadakazu, Lichtenstein, Gary R, Bressler, Brian, Peyrin-Biroulet, Laurent, Sands, Bruce E, Dignass, Axel, Abrahamovych, Orest, Abu-Farsakh, Niazy, Afanasieva, Halyna, Akpinar, Hale, Kharrat, Houssam Al, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Araki, Hiroshi, Argollo, Marjorie, Ariel, Federico ... Zureikat, Firas (2024). Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. The Lancet, 405 (10472), 33-49. doi: 10.1016/S0140-6736(24)01927-5

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

2024

Journal Article

Does improving depression symptoms in young adults with inflammatory bowel disease alter their microbiome?

Davies, Julie M., Teh, Jing Jie, Ewais, Tatjana and Begun, Jakob (2024). Does improving depression symptoms in young adults with inflammatory bowel disease alter their microbiome?. Inflammatory Bowel Diseases, 30 (12), 2428-2439. doi: 10.1093/ibd/izae121

Does improving depression symptoms in young adults with inflammatory bowel disease alter their microbiome?

2024

Journal Article

Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: a systematic review and future perspective

Parigi, Tommaso Lorenzo, Solitano, Virginia, Armuzzi, Alessandro, Acosta, Manuel Barreiro de, Begun, Jake, Ben-Horin, Shomron, Biedermann, Luc, Colombel, Jean-Frederic, Dignass, Axel, Fumery, Mathurin, Ghosh, Subrata, Kobayashi, Taku, Louis, Edouard, Magro, Fernando, Panaccione, Remo, Rausch, Astrid, Reinisch, Walter, Selinger, Christian, Jairath, Vipul, Danese, Silvio and Peyrin-Biroulet, Laurent (2024). Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: a systematic review and future perspective. United European Gastroenterology Journal, 12 (9), 1266-1279. doi: 10.1002/ueg2.12671

Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: a systematic review and future perspective

2024

Journal Article

Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial

Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark G., De Cruz, Peter, Fung, Caroline Lan-San, Redmond, Diane, Chan, Webber, Mourad, Fadi, Kermeen, Melissa and Leong, Rupert W. (2024). Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial. Clinical Gastroenterology and Hepatology, 22 (11), 2299-2308. doi: 10.1016/j.cgh.2024.04.019

Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial